Movement Alert｜Alnylam Pharmaceuticals After-Hours Rise 5.54%, Rebound Builds as Amvuttra Policy Concerns Ease

Market Focus06:17

On November 5, Alnylam Pharmaceuticals rose 5.54% in After-Hours Trading, trading at $166.8/share, with turnover of $9.8204 million.

The move followed signs that market concerns around reimbursement uncertainty tied to Amvuttra and the company’s conservative third-quarter outlook were easing after a sharp prior pullback.

Recent updates showed third-quarter revenue of $1.458 billion, above the $1.434 billion consensus estimate, while the company maintained its full-year total net product revenue outlook at $4.70 billion to $5.10 billion. Analyst commentary indicated Amvuttra sales were broadly in line with expectations, although some firms flagged that TTR revenue is trending toward the low end of guidance and that potential changes to the 2027 340B reimbursement framework could pressure hospital-channel use. Even so, several views suggested the earlier selloff had already priced in much of that risk and that underlying fundamentals remain solid.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment